Benzinga | Aug 6, 2020 04:09PM EDT

Celldex Therapeutics Q2 EPS $(0.50) Beats $(0.58) Estimate, Sales $236.00K May Not Compare To $800.00K Estimate

Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.58) by 13.79 percent. This is a 40.48 percent increase over losses of $(0.84) per share from the same period last year. The company reported quarterly sales of $236.00 thousand which missed the analyst consensus estimate of $800.00 thousand by 70.50 percent. This is a 66.99 percent decrease over sales of $715.00 thousand the same period last year.